Key result
L-carnitine reduces azithromycin-induced ST elevation incidence by ~50% and suppresses hs-cTnT in rats.
Why the study?
This study aimed to investigate the electrocardiographic and biochemical changes induced by azithromycin and evaluate the potential protective effect of L-carnitine in rats.
Does L-carnitine attenuate azithromycin-induced electrocardiographic and biochemical cardiotoxicity in a rat model?
Does L-carnitine attenuate azithromycin-induced electrocardiographic and biochemical cardiotoxicity in a rat model?
Absolute Event Rate: 1845.5% vs 3861.5%
p-value: p=<0.05
L-carnitine partially protects against azithromycin-induced cardiotoxicity, which manifested as QT shortening and ST elevation rather than QT prolongation in a rat model.
This study aimed to investigate the electrocardiographic (ECG) and biochemical changes induced by azithromycin administration in rats and to evaluate the potential protective effect of L-carnitine. Twenty-four male Wistar Albino rats were randomly divided into four groups (n=6): Control, Azithromycin (30 mg/kg/day, orally, 14 days), Azithromycin + L-Carnitine (100 mg/kg/day, i.p., 14 days), and L-Carnitine. ECG recordings were obtained and serum high-sensitivity cardiac troponin T (hs-cTnT), conventional cardiac enzymes (aspartate aminotransferase [AST], creatine kinase [CK], and lactate dehydrogenase [LDH]) and lipid profile (total cholesterol, triglycerides, high-density lipoprotein [HDL], and low-density lipoprotein [LDL]) were measured. In contrast to the prevailing view in the literature, significant shortening of QT and corrected QT (QTc) intervals was detected in the azithromycin group compared to the control group (78.00±6.07 ms and 175.08±16.37 ms, respectively; p<0.001). ST segment elevation was observed in 100% of the azithromycin group, while L-carnitine co-administration reduced this rate to 50% (p<0.05). Biochemically, hs-cTnT levels in the azithromycin group showed approximately a 6-fold increase compared to the control group (3861.50±2087.96 pg/mL; p<0.05); L-carnitine treatment significantly suppressed this elevation. No significant difference was found between groups in conventional enzymes and lipid profile (p>0.05). Azithromycin has been linked to an increased risk of adverse cardiac events, including potential myocardial injury, which?in the acute period?is characterized by QT shortening and ST elevation rather than QT prolongation. L-carnitine appears to confer partial protection against this cardiotoxicity by preserving myocardial integrity. hs-cTnT was found to be a more sensitive marker in reflecting myocardial damage compared to conventional enzymes and lipid parameters.
No takes yet. Share an insight, caveat, or question.
Eki̇ci̇ et al. (2026) studied Azithromycin-induced cardiotoxicity (n=24). L-Carnitine vs. Azithromycin alone was evaluated on Serum hs-cTnT levels (p=<0.05). L-carnitine co-administration significantly suppressed azithromycin-induced elevations in high-sensitivity cardiac troponin T and reduced the incidence of ST segment elevation from 100% to 50% in a rat model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: